User: Guest  Login
Document type:
journal article 
Author(s):
Herrlinger, K R; Diculescu, M; Fellermann, K; Hartmann, H; Howaldt, S; Nikolov, R; Petrov, A; Reindl, W; Otte, J M; Stoynov, S; Strauch, U; Sturm, A; Voiosu, R; Ammendola, A; Dietrich, B; Hentsch, B; Stange, E F 
Title:
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. 
Abstract:
Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. The objective of the study was to explore the efficacy, safety and tolerability of vidofludimus in steroid-dependent inflammatory bowel disease (IBD).The open label uncontrolled ENTRANCE study (ClinicalTrials.gov NCT00820365) has been conducted at 13 study centers in Germany, Bulgari...    »
 
Journal title abbreviation:
J Crohns Colitis 
Year:
2013 
Journal volume:
Journal issue:
Pages contribution:
636-43 
Language:
eng 
Print-ISSN:
1873-9946 
TUM Institution:
II. Medizinische Klinik und Poliklinik